Results
| Mutations: None Comorbidities: Coronary Artery Disease or other Cardiovascular Disease (e.g.,Hypertension, HTN, Myocardial infarction), Osteoporosis Comedications: Lisinopril, Metoprolol, Alendronate Treatment history: None Current regimen: RPV/TDF/FTC (Complera) |
Adherence: Administration preference: Penalize IV/IM/SC dosing CD4: Unknown Viral load: Suppressed (<50) for more than 6 months HLA-B5701: Negative Tropism: Unknown |
View results |
to help us improve HIV-ASSIST.
HIV-ASSIST calculates a regimen's weighted score on a scale of 1 to 10, in which lower values represent preferred regimens based upon current IAS and DHHS guidelines, while factoring in treatment history, comorbidities, co-medications, and other factors entered on the input page. The weighting system utilizes standardized utility weights based on current literature evidence and expert opinion. HIV-ASSIST is an educational tool and not a substitute for clinical judgement. Click on a regimen and 'Rationale' to see all steps leading to the presented weighted score. Please note that rankings would differ if if some factors were weighed more or less than those applied within HIV-ASSIST algorithms.
The Score Code is a value from 1-5 that corresponds with the chart below.
| Score Code | HIV-ASSIST Score | Efficacy (likelihood of viral suppression) | Tolerability (side-effects and pill burden) | Notes |
|---|---|---|---|---|
| 1 | ≤ 1.5 | Strong evidence | Strong evidence | Reserved for fully- or near fully- active regimens. |
| 2 | 1.5 - 2.5 | Strong or moderate evidence | Strong or moderate evidence | Includes regimens that started at better rank but were impacted by mutations, comorbidities, and drug interactions. |
| 3 | 2.5 - 4.0 | Moderate evidence | Moderate evidence | As above. Additionally, most treatment-experienced patients will see regimens in this category. |
| 4 | 4.0 - 6.0 | Moderate to poor evidence | Moderate or poor evidence | As above. Additionally, most treatment-experienced patients will see regimens in this category. |
| 5 | ≥ 6.0 | Poor evidence | Poor evidence | As above. Additionally, these represent salvage regimens in patients with limited options. |
Signifies that there may be additional regimen warnings.
Note: We do not show regimens for which there is evidence against usage.
| Score Code | Regimen | Weighted Score | Active Drugs | Total Pills | Frequency (x/day) |
|---|---|---|---|---|---|
| 1 | DTG/3TC | 1 | 2 | 1 | 1 |
| 1 | DTG/RPV | 1.01 | 2 | 1 | 1 |
| 1 | 3TC+DTG/RPV | 1.26 | 3 | 2 | 1 |
| 1 | DOR+DTG/3TC | 1.26 | 3 | 2 | 1 |
| 1 | BIC/TAF/FTC | 1.5 | 3 | 1 | 1 |
| 1 | RPV/TAF/FTC | 1.5 | 3 | 1 | 1 |
| 2 | DTG+DOR | 1.51 | 2 | 2 | 1 |
| 2 | DTG+TAF/FTC | 1.75 | 3 | 2 | 1 |
| 2 | DOR+TAF/FTC | 1.95 | 3 | 2 | 1 |
| 2 | DOR/TDF/3TC | 2 | 3 | 1 | 1 |
| 2 | DTG/ABC/3TC | 2 | 3 | 1 | 1 |
| 2 | DTG/TDF/3TC | 2 | 3 | 1 | 1 |
| 2 | EFV/TDF/FTC | 2 | 3 | 1 | 1 |
| 2 | RPV/TDF/FTC [Current regimen] | 2 | 3 | 1 | 1 |
| 2 | CAB/RPV | 2.25 | 2 | 0 | 0.03 |
| 2 | DTG+TDF/FTC | 2.25 | 3 | 2 | 1 |
| 2 | DRV/c+DTG/3TC | 2.35 | 3 | 2 | 1 |
| 2 | DOR+TDF/FTC | 2.45 | 3 | 2 | 1 |
| 2 | DRV/c+DTG/RPV | 2.46 | 3 | 2 | 1 |
| 3 | DTG+DRV/c | 2.6 | 2 | 2 | 1 |
| 3 | DOR+ABC/3TC | 2.65 | 3 | 2 | 1 |
| 3 | DRV/c+3TC | 2.75 | 2 | 2 | 1 |
| 3 | RPV+ABC/3TC | 2.9 | 3 | 2 | 1 |
| 3 | DRV/c/TAF/FTC | 3.1 | 3 | 1 | 1 |
| 3 | EFV+TAF/FTC | 3.3 | 3 | 2 | 1 |
| 3 | DRV/r+DTG/3TC | 3.4 | 3 | 3 | 1 |
| 3 | EVG/c/TAF/FTC | 3.5 | 3 | 1 | 1 |
| 3 | RAL+TAF/FTC | 3.6 | 3 | 3 | 1 |
| 3 | DTG+DRV/r | 3.65 | 2 | 3 | 1 |
| 3 | DRV/r+DTG/RPV | 3.66 | 3 | 3 | 1 |
| 3 | DTG+DRV/c+DOR | 3.66 | 3 | 3 | 1 |
| 3 | DRV/r+3TC | 3.7 | 2 | 3 | 1 |
| 3 | DRV/c+TDF/FTC | 3.95 | 3 | 2 | 1 |
| 3 | DTG+DRV/r+DOR | 3.96 | 3 | 4 | 1 |
| 4 | EVG/c/TDF/FTC | 4.1 | 3 | 1 | 1 |
| 4 | RAL+TDF/FTC | 4.2 | 3 | 3 | 1 |
| 4 | DRV/r+TAF/FTC | 4.3 | 3 | 3 | 1 |
| 4 | DRV/c+ABC/3TC | 4.45 | 3 | 2 | 1 |
| 4 | EFV+DTG/3TC | 4.45 | 3 | 3 | 2 |
| 4 | EFV+ABC/3TC | 4.5 | 3 | 2 | 1 |
| 4 | DTG+EFV | 4.7 | 2 | 3 | 2 |
| 4 | RAL+3TC | 4.7 | 2 | 3 | 1 |
| 4 | DRV/r+TDF/FTC | 4.9 | 3 | 3 | 1 |
| 4 | RAL+ABC/3TC | 4.9 | 3 | 3 | 1 |
| 4 | DTG+3TC/AZT | 5.2 | 3 | 3 | 2 |
| 4 | IBA+DTG/3TC | 5.25 | 3 | 1 | 1 |
| 4 | LEN+DTG/3TC | 5.25 | 3 | 1 | 1 |
| 4 | IBA+DTG/RPV | 5.26 | 3 | 1 | 1 |
| 4 | DOR+3TC/AZT | 5.4 | 3 | 3 | 2 |
| 4 | DRV/r+ABC/3TC | 5.4 | 3 | 3 | 1 |
| 4 | ETR+TAF/FTC | 5.4 | 3 | 3 | 2 |
| 4 | DTG+AZT+FTC | 5.4 | 3 | 4 | 2 |
| 4 | LEN+DTG/RPV | 5.51 | 3 | 1 | 1 |
| 4 | DTG+RPV/TAF/FTC | 5.51 | 4 | 2 | 1 |
| 4 | DRV/c+DOR | 5.55 | 2 | 2 | 1 |
| 4 | DOR+AZT+FTC | 5.6 | 3 | 4 | 2 |
| 4 | DTG+DRV/c/TAF/FTC | 5.6 | 4 | 2 | 1 |
| 4 | RPV+3TC/AZT | 5.65 | 3 | 3 | 2 |
| 4 | RAL+DOR+3TC | 5.65 | 3 | 4 | 1 |
| 4 | FTR+DTG/3TC | 5.7 | 3 | 3 | 2 |
| 4 | DTG+DOR+TAF/FTC | 5.71 | 4 | 3 | 1 |
| 4 | DTG+IBA+DOR | 5.76 | 3 | 2 | 1 |
| 4 | RAL+DRV/c | 5.8 | 2 | 3 | 1 |
| 4 | FTR+DTG/RPV | 5.81 | 3 | 3 | 2 |
| 4 | RPV+AZT+FTC | 5.85 | 3 | 4 | 2 |
| 4 | ETR+TDF/FTC | 5.9 | 3 | 3 | 2 |
| 4 | DTG+RPV+DRV/c/TAF/FTC | 5.91 | 5 | 3 | 1 |
| 4 | DTG+DOR+DRV/c/TAF/FTC | 5.91 | 5 | 3 | 1 |
| 5 | RAL+RPV+3TC | 6 | 3 | 4 | 1 |
| 5 | DOR+BIC/TAF/FTC | 6 | 4 | 2 | 1 |
| 5 | RPV+BIC/TAF/FTC | 6 | 4 | 2 | 1 |
| 5 | DTG+LEN+DOR | 6.01 | 3 | 2 | 1 |
| 5 | DOR+DTG/ABC/3TC | 6.01 | 4 | 2 | 1 |
| 5 | DTG+DOR/TDF/3TC | 6.01 | 4 | 2 | 1 |
| 5 | DTG+RPV/TDF/FTC | 6.01 | 4 | 2 | 1 |
| 5 | RPV+DTG/ABC/3TC | 6.01 | 4 | 2 | 1 |
| 5 | RPV+DTG/TDF/3TC | 6.01 | 4 | 2 | 1 |
| 5 | RAL+DRV/r | 6.1 | 2 | 4 | 1 |
| 5 | ETR+ABC/3TC | 6.1 | 3 | 3 | 2 |
| 5 | DRV/c+DTG/ABC/3TC | 6.1 | 4 | 2 | 1 |
| 5 | DTG+DRV/r+TAF/FTC | 6.1 | 4 | 4 | 1 |
| 5 | DTG+FTR+DOR | 6.16 | 3 | 4 | 2 |
| 5 | DTG+DRV/r+ETR | 6.2 | 3 | 6 | 2 |
| 5 | DRV/c+DTG/TDF/3TC | 6.2 | 4 | 2 | 1 |
| 5 | DRV/c+BIC/TAF/FTC | 6.2 | 4 | 2 | 1 |
| 5 | DTG+DOR+TDF/FTC | 6.21 | 4 | 3 | 1 |
| 5 | RAL+DRV/c+DOR | 6.25 | 3 | 4 | 1 |
| 5 | DTG+DRV/r+RPV/TAF/FTC | 6.36 | 5 | 4 | 1 |
| 5 | DRV/c+DOR+3TC | 6.4 | 3 | 3 | 1 |
| 5 | RAL+EFV+3TC | 6.4 | 3 | 4 | 1 |
| 5 | DRV/r+DTG/ABC/3TC | 6.4 | 4 | 3 | 1 |
| 5 | DRV/r+BIC/TAF/FTC | 6.4 | 4 | 3 | 1 |
| 5 | DTG+DRV/c+TDF/FTC | 6.4 | 4 | 3 | 1 |
| 5 | DRV/c+RPV+DTG/ABC/3TC | 6.41 | 5 | 3 | 1 |
| 5 | DRV/c+DOR+DTG/ABC/3TC | 6.41 | 5 | 3 | 1 |
| 5 | DTG+DRV/r+DOR+TAF/FTC | 6.41 | 5 | 5 | 1 |
| 5 | DTG+IBA | 6.5 | 2 | 1 | 1 |
| 5 | DTG+LEN | 6.5 | 2 | 1 | 1 |
| 5 | DRV/r+DOR | 6.5 | 2 | 3 | 1 |
| 5 | RAL+DRV/c+3TC | 6.5 | 3 | 4 | 1 |
| 5 | DRV/r+DTG/TDF/3TC | 6.5 | 4 | 3 | 1 |
| 5 | DRV/c+RPV+BIC/TAF/FTC | 6.5 | 5 | 3 | 1 |
| 5 | DRV/c+DOR+BIC/TAF/FTC | 6.5 | 5 | 3 | 1 |
| 5 | DRV/c+RPV+DTG/TDF/3TC | 6.51 | 5 | 3 | 1 |
| 5 | DTG+DRV/c+DOR/TDF/3TC | 6.51 | 5 | 3 | 1 |
| 5 | DTG+DRV/c+RPV/TDF/FTC | 6.51 | 5 | 3 | 1 |
| 5 | DTG+DRV/r+EFV | 6.55 | 3 | 5 | 2 |
| 5 | RAL+DRV/r+DOR | 6.55 | 3 | 5 | 1 |
| 5 | DRV/r+DOR+3TC | 6.6 | 3 | 4 | 1 |
| 5 | RAL+DRV/c+RPV | 6.6 | 3 | 4 | 1 |
| 5 | DRV/c+RPV | 6.65 | 2 | 2 | 1 |
| 5 | DRV/c+RPV+3TC | 6.65 | 3 | 3 | 1 |
| 5 | RAL+DOR | 6.7 | 2 | 3 | 1 |
| 5 | DTG+DRV/r+TDF/FTC | 6.7 | 4 | 4 | 1 |
| 5 | DRV/r+DOR+BIC/TAF/FTC | 6.7 | 5 | 4 | 1 |
| 5 | DRV/r+DOR+DTG/ABC/3TC | 6.71 | 5 | 4 | 1 |
| 5 | DTG+DRV/c+DOR+TDF/FTC | 6.71 | 5 | 4 | 1 |
| 5 | RAL+DRV/r+3TC | 6.8 | 3 | 5 | 1 |
| 5 | DTG+DRV/r+DOR/TDF/3TC | 6.81 | 5 | 4 | 1 |
| 5 | DTG+IBA+DRV/c | 6.85 | 3 | 2 | 1 |
| 5 | DRV/r+RPV+BIC/TAF/FTC | 6.85 | 5 | 4 | 1 |
| 5 | DRV/r+RPV+DTG/ABC/3TC | 6.86 | 5 | 4 | 1 |
| 5 | RAL+3TC/AZT | 6.9 | 3 | 4 | 2 |
| 5 | DTG+FTR | 6.95 | 2 | 3 | 2 |
| 5 | DRV/r+RPV+DTG/TDF/3TC | 6.96 | 5 | 4 | 1 |
| 5 | DTG+DRV/r+RPV/TDF/FTC | 6.96 | 5 | 4 | 1 |
| 5 | DRV/r+RPV+3TC | 7 | 3 | 4 | 1 |
| 5 | DTG+DRV/r+DOR+TDF/FTC | 7.01 | 5 | 5 | 1 |
| 5 | RAL+RPV | 7.05 | 2 | 3 | 1 |
| 5 | RAL+DRV/r+RPV | 7.05 | 3 | 5 | 1 |
| 5 | RAL+AZT+FTC | 7.1 | 3 | 5 | 2 |
| 5 | DTG+LEN+DRV/c | 7.35 | 3 | 2 | 1 |
| 5 | DRV/r+EFV | 7.4 | 2 | 3 | 1 |
| 5 | RAL+EFV | 7.45 | 2 | 3 | 1 |
| 5 | RAL+DRV/r+EFV | 7.45 | 3 | 5 | 1 |
| 5 | DRV/r+EFV+3TC | 7.5 | 3 | 4 | 1 |
| 5 | DTG+FTR+DRV/c | 7.5 | 3 | 4 | 2 |
| 5 | RAL+ETR+3TC | 7.55 | 3 | 5 | 2 |
| 5 | ETR+3TC/AZT | 7.6 | 3 | 4 | 2 |
| 5 | DRV/r+ETR+3TC | 7.65 | 3 | 5 | 2 |
| 5 | DTG+FTR+DRV/r | 7.65 | 3 | 5 | 2 |
| 5 | DTG+EFV/TDF/FTC | 7.7 | 4 | 3 | 2 |
| 5 | DRV/r+RPV | 7.75 | 2 | 3 | 1 |
| 5 | ETR+AZT+FTC | 7.8 | 3 | 5 | 2 |
| 5 | DTG+IBA+DRV/r | 7.9 | 3 | 3 | 1 |
| 5 | EFV+3TC/AZT | 7.95 | 3 | 3 | 2 |
| 5 | DTG+FTR+EFV | 8.1 | 3 | 5 | 2 |
| 5 | DTG+LEN+DRV/r | 8.15 | 3 | 3 | 1 |
| 5 | EFV+AZT+FTC | 8.15 | 3 | 4 | 2 |
| 5 | DTG+EFV+TAF/FTC | 8.15 | 4 | 4 | 2 |
| 5 | DRV/c+3TC/AZT | 8.3 | 3 | 3 | 2 |
| 5 | AZT+FTC+DTG/RPV | 8.41 | 4 | 4 | 2 |
| 5 | DTG+RPV+3TC/AZT | 8.41 | 4 | 4 | 2 |
| 5 | DTG+DOR+3TC/AZT | 8.41 | 4 | 4 | 2 |
| 5 | DRV/r+ETR | 8.45 | 2 | 4 | 2 |
| 5 | EFV+DTG/ABC/3TC | 8.45 | 4 | 3 | 2 |
| 5 | EFV+DTG/TDF/3TC | 8.45 | 4 | 3 | 2 |
| 5 | DRV/r+3TC/AZT | 8.5 | 3 | 4 | 2 |
| 5 | DRV/c+AZT+FTC | 8.5 | 3 | 4 | 2 |
| 5 | DTG+DRV/c+3TC/AZT | 8.5 | 4 | 4 | 2 |
| 5 | RAL+ETR | 8.6 | 2 | 4 | 2 |
| 5 | RAL+DRV/r+ETR | 8.6 | 3 | 6 | 2 |
| 5 | DTG+DOR+AZT+FTC | 8.61 | 4 | 5 | 2 |
| 5 | DTG+DRV/r+EFV/TDF/FTC | 8.65 | 5 | 5 | 2 |
| 5 | DTG+DRV/r+ETR+TAF/FTC | 8.65 | 5 | 7 | 2 |
| 5 | DRV/r+AZT+FTC | 8.7 | 3 | 5 | 2 |
| 5 | DTG+DRV/c+AZT+FTC | 8.7 | 4 | 5 | 2 |
| 5 | RAL+RPV/TAF/FTC | 8.8 | 4 | 3 | 1 |
| 5 | RAL+DRV/c/TAF/FTC | 8.8 | 4 | 3 | 1 |
| 5 | DTG+DRV/r+3TC/AZT | 8.8 | 4 | 5 | 2 |
| 5 | DRV/c+AZT+FTC+DTG/RPV | 8.81 | 5 | 5 | 2 |
| 5 | DTG+DRV/c+RPV+3TC/AZT | 8.81 | 5 | 5 | 2 |
| 5 | DTG+DRV/c+DOR+3TC/AZT | 8.81 | 5 | 5 | 2 |
| 5 | RAL+DOR+TAF/FTC | 8.9 | 4 | 4 | 1 |
| 5 | DTG+IBA+EFV | 8.95 | 3 | 3 | 2 |
| 5 | DRV/r+ETR+DTG/ABC/3TC | 8.95 | 5 | 6 | 2 |
| 5 | DTG+DRV/r+AZT+FTC | 9 | 4 | 6 | 2 |
| 5 | DTG+DRV/r+EFV+TAF/FTC | 9 | 5 | 6 | 2 |
| 5 | DTG+DRV/c+DOR+AZT+FTC | 9.01 | 5 | 6 | 2 |
| 5 | DRV/r+ETR+DTG/TDF/3TC | 9.05 | 5 | 6 | 2 |
| 5 | DTG+DRV/r+DOR+3TC/AZT | 9.11 | 5 | 6 | 2 |
| 5 | DOR+DRV/c/TAF/FTC | 9.2 | 4 | 2 | 1 |
| 5 | RPV+DRV/c/TAF/FTC | 9.2 | 4 | 2 | 1 |
| 5 | FTR+DRV/c+DTG/3TC | 9.25 | 4 | 4 | 2 |
| 5 | DTG+DRV/r+ETR+TDF/FTC | 9.25 | 5 | 7 | 2 |
| 5 | DRV/r+AZT+FTC+DTG/RPV | 9.26 | 5 | 6 | 2 |
| 5 | DTG+DRV/r+RPV+3TC/AZT | 9.26 | 5 | 6 | 2 |
| 5 | DOR+EVG/c/TAF/FTC | 9.3 | 4 | 2 | 1 |
| 5 | RAL+DOR/TDF/3TC | 9.3 | 4 | 3 | 1 |
| 5 | RAL+EFV/TDF/FTC | 9.3 | 4 | 3 | 1 |
| 5 | RAL+DRV/r+TAF/FTC | 9.3 | 4 | 5 | 1 |
| 5 | DRV/r+EFV+DTG/ABC/3TC | 9.3 | 5 | 5 | 2 |
| 5 | DTG+DRV/r+DOR+AZT+FTC | 9.31 | 5 | 7 | 2 |
| 5 | IBA+DRV/c+DTG/3TC | 9.35 | 4 | 2 | 1 |
| 5 | RAL+RPV/TDF/FTC | 9.4 | 4 | 3 | 1 |
| 5 | FTR+DRV/r+DTG/3TC | 9.4 | 4 | 5 | 2 |
| 5 | DRV/r+EFV+DTG/TDF/3TC | 9.4 | 5 | 5 | 2 |
| 5 | DTG+FTR+TAF/FTC | 9.45 | 4 | 4 | 2 |
| 5 | IBA+DRV/c+DTG/RPV | 9.46 | 4 | 2 | 1 |
| 5 | FTR+DRV/c+DTG/RPV | 9.46 | 4 | 4 | 2 |
| 5 | DRV+EVG/c/TAF/FTC | 9.5 | 4 | 2 | 1 |
| 5 | RAL+DOR+TDF/FTC | 9.5 | 4 | 4 | 1 |
| 5 | LEN+IBA+DTG/RPV | 9.51 | 4 | 1 | 1 |
| 5 | DRV/r+RPV/TAF/FTC | 9.55 | 4 | 3 | 1 |
| 5 | DRV/r+DOR+TAF/FTC | 9.6 | 4 | 4 | 1 |
| 5 | RAL+DOR+ABC/3TC | 9.6 | 4 | 4 | 1 |
| 5 | IBA+DRV/r+DTG/3TC | 9.65 | 4 | 3 | 1 |
| 5 | RAL+EFV+TAF/FTC | 9.65 | 4 | 4 | 1 |
| 5 | FTR+DTG/ABC/3TC | 9.7 | 4 | 3 | 2 |
| 5 | RAL+DRV/c+ABC/3TC | 9.7 | 4 | 4 | 1 |
| 5 | RAL+DRV/c+TDF/FTC | 9.7 | 4 | 4 | 1 |
| 5 | DTG+IBA+TAF/FTC | 9.75 | 4 | 2 | 1 |
| 5 | FTR+DTG/TDF/3TC | 9.75 | 4 | 3 | 2 |
| 5 | FTR+BIC/TAF/FTC | 9.75 | 4 | 3 | 2 |
| 5 | DTG+LEN+IBA+DOR | 9.76 | 4 | 2 | 1 |
| 5 | FTR+DRV/r+DTG/RPV | 9.76 | 4 | 5 | 2 |
| 5 | DOR+EVG/c/TDF/FTC | 9.8 | 4 | 2 | 1 |
| 5 | DRV/c+DOR/TDF/3TC | 9.8 | 4 | 2 | 1 |
| 5 | DRV/c+RPV/TDF/FTC | 9.8 | 4 | 2 | 1 |
| 5 | RPV+EVG/c/TAF/FTC | 9.8 | 4 | 2 | 1 |
| 5 | DTG+FTR+DRV/c/TAF/FTC | 9.8 | 5 | 4 | 2 |
| 5 | DTG+FTR+DRV/c+DOR | 9.81 | 4 | 5 | 2 |
| 5 | LEN+DRV/c+DTG/3TC | 9.85 | 4 | 2 | 1 |
| 5 | DTG+IBA+DRV/c/TAF/FTC | 9.85 | 5 | 2 | 1 |
| 5 | LEN+DRV/r+DTG/3TC | 9.9 | 4 | 3 | 1 |
| 5 | DTG+IBA+DRV/c+DOR | 9.91 | 4 | 3 | 1 |
| 5 | IBA+DRV/r+DTG/RPV | 9.91 | 4 | 3 | 1 |
| 5 | DTG+FTR+TDF/FTC | 9.95 | 4 | 4 | 2 |
| 5 | RAL+RPV+ABC/3TC | 9.95 | 4 | 4 | 1 |
| 5 | DTG+FTR+DRV/r+DOR | 9.96 | 4 | 6 | 2 |
| 5 | DTG+LEN+TAF/FTC | 10 | 4 | 2 | 1 |
| 5 | DRV/r+DOR/TDF/3TC | 10 | 4 | 3 | 1 |
| 5 | DRV/c+DOR+TDF/FTC | 10 | 4 | 3 | 1 |
| 5 | RAL+DRV/r+ABC/3TC | 10 | 4 | 5 | 1 |
| 5 | RAL+DRV/r+TDF/FTC | 10 | 4 | 5 | 1 |
| 5 | FTR+IBA+DTG/RPV | 10.06 | 4 | 3 | 2 |
| 5 | DTG+LEN+IBA+DRV/c | 10.1 | 4 | 2 | 1 |
| 5 | DRV/c+DOR+ABC/3TC | 10.1 | 4 | 3 | 1 |
| 5 | DRV/r+EFV/TDF/FTC | 10.15 | 4 | 3 | 1 |
| 5 | DRV/r+RPV/TDF/FTC | 10.15 | 4 | 3 | 1 |
| 5 | DTG+LEN+IBA+DRV/r | 10.15 | 4 | 3 | 1 |
| 5 | DTG+FTR+DRV/r+TAF/FTC | 10.15 | 5 | 6 | 2 |
| 5 | DRV/r+DOR+TDF/FTC | 10.2 | 4 | 4 | 1 |
| 5 | LEN+DRV/c+DTG/RPV | 10.21 | 4 | 2 | 1 |
| 5 | DTG+IBA+DRV/r+DOR | 10.21 | 4 | 4 | 1 |
| 5 | IBA+DTG/ABC/3TC | 10.25 | 4 | 1 | 1 |
| 5 | IBA+DTG/TDF/3TC | 10.25 | 4 | 1 | 1 |
| 5 | IBA+BIC/TAF/FTC | 10.25 | 4 | 1 | 1 |
| 5 | LEN+DTG/ABC/3TC | 10.25 | 4 | 1 | 1 |
| 5 | DTG+IBA+TDF/FTC | 10.25 | 4 | 2 | 1 |
| 5 | FTR+DRV/c+DTG/ABC/3TC | 10.25 | 5 | 4 | 2 |
| 5 | DRV/r+DOR+ABC/3TC | 10.3 | 4 | 4 | 1 |
| 5 | DRV/c+RPV+ABC/3TC | 10.35 | 4 | 3 | 1 |
| 5 | RAL+EFV+ABC/3TC | 10.35 | 4 | 4 | 1 |
| 5 | DTG+EFV+3TC/AZT | 10.35 | 4 | 5 | 2 |
| 5 | IBA+DRV/c+DTG/ABC/3TC | 10.35 | 5 | 2 | 1 |
| 5 | DTG+IBA+DRV/r+TAF/FTC | 10.35 | 5 | 4 | 1 |
| 5 | FTR+DRV/c+DTG/TDF/3TC | 10.4 | 5 | 4 | 2 |
| 5 | FTR+DRV/c+BIC/TAF/FTC | 10.4 | 5 | 4 | 2 |
| 5 | FTR+DRV/r+DTG/ABC/3TC | 10.4 | 5 | 5 | 2 |
| 5 | LEN+DRV/r+DTG/RPV | 10.41 | 4 | 3 | 1 |
| 5 | DTG+FTR+IBA+DOR | 10.41 | 4 | 4 | 2 |
| 5 | IBA+DRV/c+DTG/TDF/3TC | 10.45 | 5 | 2 | 1 |
| 5 | IBA+DRV/c+BIC/TAF/FTC | 10.45 | 5 | 2 | 1 |
| 5 | FTR+DRV/r+BIC/TAF/FTC | 10.45 | 5 | 5 | 2 |
| 5 | LEN+DTG/TDF/3TC | 10.5 | 4 | 1 | 1 |
| 5 | LEN+BIC/TAF/FTC | 10.5 | 4 | 1 | 1 |
| 5 | DTG+LEN+TDF/FTC | 10.5 | 4 | 2 | 1 |
| 5 | DRV/r+EFV+TAF/FTC | 10.5 | 4 | 4 | 1 |
| 5 | DTG+EFV+AZT+FTC | 10.55 | 4 | 6 | 2 |
| 5 | FTR+DRV/r+DTG/TDF/3TC | 10.55 | 5 | 5 | 2 |
| 5 | LEN+FTR+DTG/RPV | 10.56 | 4 | 3 | 2 |
| 5 | DTG+LEN+DRV/c/TAF/FTC | 10.6 | 5 | 2 | 1 |
| 5 | DTG+FTR+DRV/c+TDF/FTC | 10.6 | 5 | 5 | 2 |
| 5 | DRV/r+ETR+TAF/FTC | 10.65 | 4 | 5 | 2 |
| 5 | DTG+IBA+DRV/c+TDF/FTC | 10.65 | 5 | 3 | 1 |
| 5 | IBA+DRV/r+DTG/ABC/3TC | 10.65 | 5 | 3 | 1 |
| 5 | IBA+DRV/r+BIC/TAF/FTC | 10.65 | 5 | 3 | 1 |
| 5 | DTG+LEN+DRV/c+DOR | 10.66 | 4 | 3 | 1 |
| 5 | DRV/r+RPV+ABC/3TC | 10.7 | 4 | 4 | 1 |
| 5 | DTG+LEN+DRV/r+DOR | 10.71 | 4 | 4 | 1 |
| 5 | DTG+FTR+IBA+DRV/c | 10.75 | 4 | 4 | 2 |
| 5 | IBA+DRV/r+DTG/TDF/3TC | 10.75 | 5 | 3 | 1 |
| 5 | DTG+FTR+DRV/r+TDF/FTC | 10.75 | 5 | 6 | 2 |
| 5 | RAL+ETR+TAF/FTC | 10.8 | 4 | 5 | 2 |
| 5 | LEN+DRV/c+DTG/ABC/3TC | 10.85 | 5 | 2 | 1 |
| 5 | DTG+LEN+DRV/r+TAF/FTC | 10.85 | 5 | 4 | 1 |
| 5 | DTG+DRV/r+ETR+3TC/AZT | 10.85 | 5 | 8 | 2 |
| 5 | RAL+IBA | 10.9 | 2 | 2 | 1 |
| 5 | DTG+FTR+IBA+DRV/r | 10.9 | 4 | 5 | 2 |
| 5 | LEN+DRV/r+DTG/ABC/3TC | 10.9 | 5 | 3 | 1 |
| 5 | DTG+LEN+FTR+DOR | 10.91 | 4 | 4 | 2 |
| 5 | DTG+IBA+DRV/r+TDF/FTC | 10.95 | 5 | 4 | 1 |
| 5 | RAL+LEN | 10.99 | 2 | 2 | 1 |
| 5 | DTG+DRV/r+ETR+AZT+FTC | 11.05 | 5 | 9 | 2 |
| 5 | LEN+DRV/r+BIC/TAF/FTC | 11.15 | 5 | 3 | 1 |
| 5 | DRV/r+EFV+ABC/3TC | 11.2 | 4 | 4 | 1 |
| 5 | LEN+DRV/c+DTG/TDF/3TC | 11.2 | 5 | 2 | 1 |
| 5 | LEN+DRV/c+BIC/TAF/FTC | 11.2 | 5 | 2 | 1 |
| 5 | DTG+DRV/r+EFV+3TC/AZT | 11.2 | 5 | 7 | 2 |
| 5 | IBA+DRV/c | 11.25 | 2 | 1 | 1 |
| 5 | DRV/r+ETR+TDF/FTC | 11.25 | 4 | 5 | 2 |
| 5 | LEN+DRV/r+DTG/TDF/3TC | 11.25 | 5 | 3 | 1 |
| 5 | DRV/r+ETR+ABC/3TC | 11.35 | 4 | 5 | 2 |
| 5 | RAL+FTR | 11.39 | 2 | 4 | 2 |
| 5 | RAL+FTR+3TC | 11.4 | 3 | 5 | 2 |
| 5 | DTG+LEN+FTR+DRV/r | 11.4 | 4 | 5 | 2 |
| 5 | RAL+ETR+TDF/FTC | 11.4 | 4 | 5 | 2 |
| 5 | DTG+LEN+DRV/c+TDF/FTC | 11.4 | 5 | 3 | 1 |
| 5 | DTG+DRV/r+EFV+AZT+FTC | 11.4 | 5 | 8 | 2 |
| 5 | DTG+LEN+DRV/r+TDF/FTC | 11.45 | 5 | 4 | 1 |
| 5 | IBA+DRV/r | 11.5 | 2 | 2 | 1 |
| 5 | DTG+LEN+FTR+DRV/c | 11.5 | 4 | 4 | 2 |
| 5 | RAL+ETR+ABC/3TC | 11.5 | 4 | 5 | 2 |
| 5 | RAL+DOR+DRV/c/TAF/FTC | 11.5 | 5 | 4 | 1 |
| 5 | IBA+DRV/c+3TC | 11.55 | 3 | 2 | 1 |
| 5 | RAL+FTR+DOR | 11.55 | 3 | 5 | 2 |
| 5 | DTG+FTR+3TC/AZT | 11.6 | 4 | 5 | 2 |
| 5 | RAL+DOR+3TC/AZT | 11.6 | 4 | 5 | 2 |
| 5 | RAL+RPV+DRV/c/TAF/FTC | 11.6 | 5 | 4 | 1 |
| 5 | IBA+DRV/c+DOR | 11.65 | 3 | 2 | 1 |
| 5 | RAL+DRV/c+3TC/AZT | 11.7 | 4 | 5 | 2 |
| 5 | LEN+RAL+3TC | 11.75 | 3 | 3 | 1 |
| 5 | RAL+IBA+3TC | 11.75 | 3 | 3 | 1 |
| 5 | DTG+FTR+AZT+FTC | 11.8 | 4 | 6 | 2 |
| 5 | RAL+DOR+AZT+FTC | 11.8 | 4 | 6 | 2 |
| 5 | DTG+FTR+DRV/r+ETR | 11.8 | 4 | 8 | 2 |
| 5 | LEN+DRV/c | 11.84 | 2 | 1 | 1 |
| 5 | LEN+DRV/r | 11.84 | 2 | 2 | 1 |
| 5 | IBA+DRV/c+RPV | 11.9 | 3 | 2 | 1 |
| 5 | RAL+IBA+DOR | 11.9 | 3 | 3 | 1 |
| 5 | RAL+DRV/c+AZT+FTC | 11.9 | 4 | 6 | 2 |
| 5 | RAL+RPV+3TC/AZT | 11.95 | 4 | 5 | 2 |
| 5 | RAL+FTR+RPV | 12 | 3 | 5 | 2 |
| 5 | RAL+DRV/r+3TC/AZT | 12 | 4 | 6 | 2 |
| 5 | RAL+DRV/r+DOR+TAF/FTC | 12 | 5 | 6 | 1 |
| 5 | FTR+DRV/c | 12.04 | 2 | 3 | 2 |
| 5 | LEN+DRV/c+3TC | 12.05 | 3 | 2 | 1 |
| 5 | DTG+FTR+DRV/r+EFV | 12.05 | 4 | 7 | 2 |
| 5 | RAL+DRV/r+RPV/TAF/FTC | 12.05 | 5 | 5 | 1 |
| 5 | FTR+DRV/r | 12.09 | 2 | 4 | 2 |
| 5 | DRV/c+DOR+3TC/AZT | 12.1 | 4 | 4 | 2 |
| 5 | LEN+RAL+DOR | 12.15 | 3 | 3 | 1 |
| 5 | RAL+RPV+AZT+FTC | 12.15 | 4 | 6 | 2 |
| 5 | DTG+FTR+DRV/c+3TC/AZT | 12.15 | 5 | 6 | 2 |
| 5 | FTR+DRV/c+3TC | 12.2 | 3 | 4 | 2 |
| 5 | RAL+FTR+DRV/c | 12.2 | 3 | 5 | 2 |
| 5 | RAL+DRV/r+AZT+FTC | 12.2 | 4 | 7 | 2 |
| 5 | DRV+DOR+EVG/c/TAF/FTC | 12.2 | 5 | 3 | 1 |
| 5 | RAL+DRV/c+DOR/TDF/3TC | 12.2 | 5 | 4 | 1 |
| 5 | RAL+IBA+RPV | 12.25 | 3 | 3 | 1 |
| 5 | FTR+DRV/r+3TC | 12.25 | 3 | 5 | 2 |
| 5 | FTR+DRV/c+DOR | 12.3 | 3 | 4 | 2 |
| 5 | RAL+FTR+EFV | 12.3 | 3 | 5 | 2 |
| 5 | DRV/r+DOR+3TC/AZT | 12.3 | 4 | 5 | 2 |
| 5 | DRV/c+DOR+AZT+FTC | 12.3 | 4 | 5 | 2 |
| 5 | RAL+DRV/c+RPV/TDF/FTC | 12.3 | 5 | 4 | 1 |
| 5 | DTG+FTR+DRV/r+3TC/AZT | 12.3 | 5 | 7 | 2 |
| 5 | FTR+DRV/r+DOR | 12.35 | 3 | 5 | 2 |
| 5 | RAL+FTR+DRV/r | 12.35 | 3 | 6 | 2 |
| 5 | DRV/c+RPV+3TC/AZT | 12.35 | 4 | 4 | 2 |
| 5 | DTG+FTR+IBA+EFV | 12.35 | 4 | 5 | 2 |
| 5 | RAL+EFV+3TC/AZT | 12.35 | 4 | 5 | 2 |
| 5 | DTG+FTR+DRV/c+AZT+FTC | 12.35 | 5 | 7 | 2 |
| 5 | LEN+DRV/c+DOR | 12.4 | 3 | 2 | 1 |
| 5 | RAL+DRV/c+DOR+ABC/3TC | 12.4 | 5 | 5 | 1 |
| 5 | RAL+DRV/c+DOR+TDF/FTC | 12.4 | 5 | 5 | 1 |
| 5 | DTG+LEN+3TC/AZT | 12.45 | 4 | 3 | 2 |
| 5 | DTG+IBA+3TC/AZT | 12.45 | 4 | 3 | 2 |
| 5 | DTG+IBA+DRV/r+ETR | 12.45 | 4 | 6 | 2 |
| 5 | IBA+DRV/r+3TC | 12.5 | 3 | 3 | 1 |
| 5 | LEN+RAL+RPV | 12.5 | 3 | 3 | 1 |
| 5 | DRV/r+DOR+AZT+FTC | 12.5 | 4 | 6 | 2 |
| 5 | RAL+DRV/r+DOR/TDF/3TC | 12.5 | 5 | 5 | 1 |
| 5 | DTG+FTR+DRV/r+AZT+FTC | 12.5 | 5 | 8 | 2 |
| 5 | DRV/c+RPV+AZT+FTC | 12.55 | 4 | 5 | 2 |
| 5 | RAL+EFV+AZT+FTC | 12.55 | 4 | 6 | 2 |
| 5 | IBA+DRV/r+DOR | 12.6 | 3 | 3 | 1 |
| 5 | LEN+DRV/c+RPV | 12.65 | 3 | 2 | 1 |
| 5 | RAL+IBA+EFV | 12.65 | 3 | 3 | 1 |
| 5 | FTR+DRV/c+RPV | 12.65 | 3 | 4 | 2 |
| 5 | DTG+LEN+AZT+FTC | 12.65 | 4 | 4 | 2 |
| 5 | DTG+IBA+AZT+FTC | 12.65 | 4 | 4 | 2 |
| 5 | RAL+DRV/r+EFV/TDF/FTC | 12.65 | 5 | 5 | 1 |
| 5 | DRV/r+RPV+3TC/AZT | 12.7 | 4 | 5 | 2 |
| 5 | DRV+RPV+EVG/c/TAF/FTC | 12.7 | 5 | 3 | 1 |
| 5 | RAL+DRV/r+DOR+ABC/3TC | 12.7 | 5 | 6 | 1 |
| 5 | RAL+DRV/r+DOR+TDF/FTC | 12.7 | 5 | 6 | 1 |
| 5 | LEN+DRV/r+3TC | 12.75 | 3 | 3 | 1 |
| 5 | DTG+IBA+DRV/c+3TC/AZT | 12.75 | 5 | 4 | 2 |
| 5 | RAL+DRV/c+RPV+ABC/3TC | 12.75 | 5 | 5 | 1 |
| 5 | RAL+DRV/r+RPV/TDF/FTC | 12.75 | 5 | 5 | 1 |
| 5 | RAL+IBA+DRV/c | 12.8 | 3 | 3 | 1 |
| 5 | RAL+LEN+DRV/c | 12.8 | 3 | 3 | 1 |
| 5 | DTG+IBA+DRV/r+EFV | 12.8 | 4 | 5 | 2 |
| 5 | RAL+LEN+DRV/r | 12.85 | 3 | 4 | 1 |
| 5 | FTR+DRV/r+RPV | 12.85 | 3 | 5 | 2 |
| 5 | DRV/r+ETR+3TC/AZT | 12.85 | 4 | 6 | 2 |
| 5 | DRV/r+RPV+AZT+FTC | 12.9 | 4 | 6 | 2 |
| 5 | RAL+DRV/r+EFV+TAF/FTC | 12.9 | 5 | 6 | 1 |
| 5 | DTG+IBA+DRV/c+AZT+FTC | 12.95 | 5 | 5 | 2 |
| 5 | IBA+DRV/r+RPV | 13 | 3 | 3 | 1 |
| 5 | FTR+DRV/r+ETR | 13 | 3 | 6 | 2 |
| 5 | RAL+ETR+3TC/AZT | 13 | 4 | 6 | 2 |
| 5 | RAL+FTR+ETR | 13.05 | 3 | 6 | 2 |
| 5 | DRV/r+ETR+AZT+FTC | 13.05 | 4 | 7 | 2 |
| 5 | DTG+IBA+DRV/r+3TC/AZT | 13.05 | 5 | 5 | 2 |
| 5 | LEN+DRV/r+DOR | 13.1 | 3 | 3 | 1 |
| 5 | RAL+IBA+DRV/r | 13.1 | 3 | 4 | 1 |
| 5 | DRV/r+EFV+3TC/AZT | 13.2 | 4 | 5 | 2 |
| 5 | RAL+ETR+AZT+FTC | 13.2 | 4 | 7 | 2 |
| 5 | RAL+DRV/r+RPV+ABC/3TC | 13.2 | 5 | 6 | 1 |
| 5 | FTR+DRV/r+EFV | 13.25 | 3 | 5 | 2 |
| 5 | DTG+LEN+DRV/c+3TC/AZT | 13.25 | 5 | 4 | 2 |
| 5 | DTG+IBA+DRV/r+AZT+FTC | 13.25 | 5 | 6 | 2 |
| 5 | DTG+LEN+DRV/r+3TC/AZT | 13.3 | 5 | 5 | 2 |
| 5 | DRV/r+EFV+AZT+FTC | 13.4 | 4 | 6 | 2 |
| 5 | DTG+LEN+DRV/c+AZT+FTC | 13.45 | 5 | 5 | 2 |
| 5 | IBA+DRV/r+EFV | 13.5 | 3 | 3 | 1 |
| 5 | LEN+DRV/r+RPV | 13.5 | 3 | 3 | 1 |
| 5 | DTG+LEN+DRV/r+AZT+FTC | 13.5 | 5 | 6 | 2 |
| 5 | RAL+DRV/r+EFV+ABC/3TC | 13.6 | 5 | 6 | 1 |
| 5 | IBA+DRV/r+ETR | 13.65 | 3 | 4 | 2 |
| 5 | RAL+IBA+ETR | 13.8 | 3 | 4 | 2 |
| 5 | RAL+DRV/r+ETR+TAF/FTC | 14.05 | 5 | 7 | 2 |
| 5 | RAL+DRV/c+DOR+3TC/AZT | 14.4 | 5 | 6 | 2 |
| 5 | DTG+LEN+DRV/r+ETR | 14.6 | 4 | 6 | 2 |
| 5 | RAL+DRV/c+DOR+AZT+FTC | 14.6 | 5 | 7 | 2 |
| 5 | RAL+FTR+TAF/FTC | 14.65 | 4 | 5 | 2 |
| 5 | RAL+FTR+DRV/c+3TC | 14.65 | 4 | 6 | 2 |
| 5 | RAL+DRV/r+DOR+3TC/AZT | 14.7 | 5 | 7 | 2 |
| 5 | RAL+IBA+DRV/c+3TC | 14.75 | 4 | 4 | 1 |
| 5 | RAL+FTR+DRV/c+DOR | 14.75 | 4 | 6 | 2 |
| 5 | RAL+DRV/c+RPV+3TC/AZT | 14.75 | 5 | 6 | 2 |
| 5 | RAL+DRV/r+ETR+ABC/3TC | 14.75 | 5 | 7 | 2 |
| 5 | RAL+DRV/r+ETR+TDF/FTC | 14.75 | 5 | 7 | 2 |
| 5 | RAL+FTR+DRV/r+3TC | 14.8 | 4 | 7 | 2 |
| 5 | RAL+IBA+DRV/c+DOR | 14.85 | 4 | 4 | 1 |
| 5 | RAL+FTR+DRV/r+DOR | 14.9 | 4 | 7 | 2 |
| 5 | RAL+DRV/r+DOR+AZT+FTC | 14.9 | 5 | 8 | 2 |
| 5 | RAL+DRV/c+RPV+AZT+FTC | 14.95 | 5 | 7 | 2 |
| 5 | FTR+EVG/c/TAF/FTC | 15.05 | 4 | 3 | 2 |
| 5 | RAL+IBA+DRV/r+3TC | 15.05 | 4 | 5 | 1 |
| 5 | FTR+DRV/c/TAF/FTC | 15.1 | 4 | 3 | 2 |
| 5 | LEN+RAL+IBA+DOR | 15.1 | 4 | 3 | 1 |
| 5 | RAL+IBA+DRV/r+DOR | 15.15 | 4 | 5 | 1 |
| 5 | RAL+LEN+TAF/FTC | 15.2 | 4 | 3 | 1 |
| 5 | RAL+IBA+TAF/FTC | 15.2 | 4 | 3 | 1 |
| 5 | RAL+IBA+DRV/c+RPV | 15.2 | 4 | 4 | 1 |
| 5 | RAL+FTR+DRV/c+RPV | 15.2 | 4 | 6 | 2 |
| 5 | RAL+DRV/r+RPV+3TC/AZT | 15.2 | 5 | 7 | 2 |
| 5 | LEN+RAL+DRV/c+3TC | 15.25 | 4 | 4 | 1 |
| 5 | RAL+FTR+TDF/FTC | 15.25 | 4 | 5 | 2 |
| 5 | LEN+RAL+IBA+DRV/c | 15.3 | 4 | 3 | 1 |
| 5 | LEN+RAL+DRV/r+3TC | 15.3 | 4 | 5 | 1 |
| 5 | RAL+FTR+ABC/3TC | 15.3 | 4 | 5 | 2 |
| 5 | LEN+RAL+IBA+DRV/r | 15.35 | 4 | 4 | 1 |
| 5 | FTR+DRV/r+TAF/FTC | 15.35 | 4 | 5 | 2 |
| 5 | RAL+FTR+DRV/c/TAF/FTC | 15.4 | 5 | 5 | 2 |
| 5 | RAL+DRV/r+RPV+AZT+FTC | 15.4 | 5 | 8 | 2 |
| 5 | LEN+RAL+IBA+RPV | 15.45 | 4 | 3 | 1 |
| 5 | RAL+IBA+DRV/c/TAF/FTC | 15.45 | 5 | 3 | 1 |
| 5 | RAL+FTR+DRV/r+RPV | 15.5 | 4 | 7 | 2 |
| 5 | FTR+EVG/c/TDF/FTC | 15.55 | 4 | 3 | 2 |
| 5 | IBA+DRV/c/TAF/FTC | 15.6 | 4 | 1 | 1 |
| 5 | LEN+RAL+DRV/c+DOR | 15.6 | 4 | 4 | 1 |
| 5 | RAL+DRV/r+EFV+3TC/AZT | 15.6 | 5 | 7 | 2 |
| 5 | RAL+LEN+ABC/3TC | 15.65 | 4 | 3 | 1 |
| 5 | LEN+RAL+DRV/r+DOR | 15.65 | 4 | 5 | 1 |
| 5 | RAL+IBA+DRV/r+RPV | 15.65 | 4 | 5 | 1 |
| 5 | LEN+RAL+ETR | 15.7 | 3 | 4 | 2 |
| 5 | RAL+FTR+IBA+DOR | 15.75 | 4 | 5 | 2 |
| 5 | RAL+FTR+DRV/r+TAF/FTC | 15.75 | 5 | 7 | 2 |
| 5 | LEN+DRV/r+ETR | 15.8 | 3 | 4 | 2 |
| 5 | IBA+EVG/c/TAF/FTC | 15.8 | 4 | 1 | 1 |
| 5 | IBA+DRV/r+TAF/FTC | 15.8 | 4 | 3 | 1 |
| 5 | RAL+LEN+TDF/FTC | 15.8 | 4 | 3 | 1 |
| 5 | RAL+IBA+TDF/FTC | 15.8 | 4 | 3 | 1 |
| 5 | RAL+FTR+DRV/r+EFV | 15.8 | 4 | 7 | 2 |
| 5 | RAL+DRV/r+EFV+AZT+FTC | 15.8 | 5 | 8 | 2 |
| 5 | FTR+DRV+EVG/c/TAF/FTC | 15.85 | 5 | 4 | 2 |
| 5 | RAL+IBA+ABC/3TC | 15.9 | 4 | 3 | 1 |
| 5 | FTR+DRV/c+TDF/FTC | 15.9 | 4 | 4 | 2 |
| 5 | FTR+DRV/c+ABC/3TC | 15.95 | 4 | 4 | 2 |
| 5 | LEN+RAL+DRV/c+RPV | 15.95 | 4 | 4 | 1 |
| 5 | FTR+DRV/r+TDF/FTC | 15.95 | 4 | 5 | 2 |
| 5 | RAL+FTR+IBA+DRV/c | 15.95 | 4 | 5 | 2 |
| 5 | RAL+IBA+DRV/r+TAF/FTC | 15.95 | 5 | 5 | 1 |
| 5 | FTR+DRV/r+ABC/3TC | 16 | 4 | 5 | 2 |
| 5 | LEN+EVG/c/TAF/FTC | 16.05 | 4 | 1 | 1 |
| 5 | LEN+DRV/r+TAF/FTC | 16.05 | 4 | 3 | 1 |
| 5 | LEN+IBA+DRV/r+DOR | 16.05 | 4 | 3 | 1 |
| 5 | RAL+IBA+DRV/r+EFV | 16.05 | 4 | 5 | 1 |
| 5 | LEN+DRV/c/TAF/FTC | 16.1 | 4 | 1 | 1 |
| 5 | LEN+IBA+DRV/c+DOR | 16.1 | 4 | 2 | 1 |
| 5 | RAL+FTR+IBA+DRV/r | 16.1 | 4 | 6 | 2 |
| 5 | LEN+RAL+DRV/r+RPV | 16.15 | 4 | 5 | 1 |
| 5 | IBA+DRV+EVG/c/TAF/FTC | 16.15 | 5 | 2 | 1 |
| 5 | IBA+DRV/c+TDF/FTC | 16.2 | 4 | 2 | 1 |
| 5 | RAL+FTR+IBA+RPV | 16.2 | 4 | 5 | 2 |
| 5 | LEN+RAL+DRV/c/TAF/FTC | 16.2 | 5 | 3 | 1 |
| 5 | LEN+RAL+FTR+DOR | 16.25 | 4 | 5 | 2 |
| 5 | RAL+FTR+DRV/c+ABC/3TC | 16.25 | 5 | 6 | 2 |
| 5 | RAL+DRV/r+ETR+3TC/AZT | 16.25 | 5 | 8 | 2 |
| 5 | IBA+EVG/c/TDF/FTC | 16.3 | 4 | 1 | 1 |
| 5 | IBA+DRV/c+ABC/3TC | 16.3 | 4 | 2 | 1 |
| 5 | RAL+FTR+DRV/c+TDF/FTC | 16.3 | 5 | 6 | 2 |
| 5 | LEN+IBA+DRV/c+RPV | 16.35 | 4 | 2 | 1 |
| 5 | RAL+IBA+DRV/c+ABC/3TC | 16.35 | 5 | 4 | 1 |
| 5 | RAL+IBA+DRV/c+TDF/FTC | 16.35 | 5 | 4 | 1 |
| 5 | IBA+DRV/r+TDF/FTC | 16.4 | 4 | 3 | 1 |
| 5 | RAL+FTR+DRV/r+ABC/3TC | 16.4 | 5 | 7 | 2 |
| 5 | LEN+IBA+DRV/r+RPV | 16.45 | 4 | 3 | 1 |
| 5 | LEN+RAL+DRV/r+TAF/FTC | 16.45 | 5 | 5 | 1 |
| 5 | RAL+FTR+DRV/r+TDF/FTC | 16.45 | 5 | 7 | 2 |
| 5 | RAL+DRV/r+ETR+AZT+FTC | 16.45 | 5 | 9 | 2 |
| 5 | IBA+DRV/r+ABC/3TC | 16.5 | 4 | 3 | 1 |
| 5 | LEN+DRV/r+ABC/3TC | 16.5 | 4 | 3 | 1 |
| 5 | FTR+IBA+DRV/c+DOR | 16.5 | 4 | 4 | 2 |
| 5 | RAL+FTR+IBA+EFV | 16.5 | 4 | 5 | 2 |
| 5 | LEN+EVG/c/TDF/FTC | 16.55 | 4 | 1 | 1 |
| 5 | LEN+DRV/c+ABC/3TC | 16.55 | 4 | 2 | 1 |
| 5 | FTR+IBA+DRV/r+DOR | 16.55 | 4 | 5 | 2 |
| 5 | RAL+FTR+DRV/r+ETR | 16.55 | 4 | 8 | 2 |
| 5 | LEN+RAL+FTR+DRV/r | 16.6 | 4 | 6 | 2 |
| 5 | LEN+DRV/r+TDF/FTC | 16.65 | 4 | 3 | 1 |
| 5 | LEN+DRV+EVG/c/TAF/FTC | 16.65 | 5 | 2 | 1 |
| 5 | RAL+IBA+DRV/r+ABC/3TC | 16.65 | 5 | 5 | 1 |
| 5 | RAL+IBA+DRV/r+TDF/FTC | 16.65 | 5 | 5 | 1 |
| 5 | LEN+DRV/c+TDF/FTC | 16.7 | 4 | 2 | 1 |
| 5 | LEN+RAL+FTR+DRV/c | 16.7 | 4 | 5 | 2 |
| 5 | LEN+RAL+FTR+RPV | 16.7 | 4 | 5 | 2 |
| 5 | RAL+FTR+3TC/AZT | 16.8 | 4 | 6 | 2 |
| 5 | FTR+IBA+DRV/c+RPV | 16.85 | 4 | 4 | 2 |
| 5 | LEN+RAL+DRV/c+ABC/3TC | 16.85 | 5 | 4 | 1 |
| 5 | LEN+RAL+DRV/r+ABC/3TC | 16.9 | 5 | 5 | 1 |
| 5 | RAL+FTR+AZT+FTC | 17 | 4 | 7 | 2 |
| 5 | FTR+IBA+DRV/r+RPV | 17.05 | 4 | 5 | 2 |
| 5 | LEN+RAL+DRV/c+TDF/FTC | 17.1 | 5 | 4 | 1 |
| 5 | LEN+RAL+DRV/r+TDF/FTC | 17.15 | 5 | 5 | 1 |
| 5 | FTR+IBA+DRV/r+ETR | 17.2 | 4 | 6 | 2 |
| 5 | RAL+IBA+DRV/r+ETR | 17.2 | 4 | 6 | 2 |
| 5 | RAL+FTR+IBA+ETR | 17.25 | 4 | 6 | 2 |
| 5 | LEN+FTR+DRV/r+DOR | 17.3 | 4 | 5 | 2 |
| 5 | FTR+DRV/c+3TC/AZT | 17.45 | 4 | 5 | 2 |
| 5 | FTR+IBA+DRV/r+EFV | 17.45 | 4 | 5 | 2 |
| 5 | LEN+FTR+DRV/c+DOR | 17.5 | 4 | 4 | 2 |
| 5 | FTR+DRV/r+3TC/AZT | 17.5 | 4 | 6 | 2 |
| 5 | RAL+LEN+3TC/AZT | 17.65 | 4 | 4 | 2 |
| 5 | FTR+DRV/c+AZT+FTC | 17.65 | 4 | 6 | 2 |
| 5 | FTR+DRV/r+AZT+FTC | 17.7 | 4 | 7 | 2 |
| 5 | RAL+FTR+DRV/c+3TC/AZT | 17.75 | 5 | 7 | 2 |
| 5 | LEN+FTR+DRV/r+RPV | 17.8 | 4 | 5 | 2 |
| 5 | LEN+FTR+DRV/c+RPV | 17.85 | 4 | 4 | 2 |
| 5 | RAL+LEN+AZT+FTC | 17.85 | 4 | 5 | 2 |
| 5 | RAL+IBA+3TC/AZT | 17.9 | 4 | 4 | 2 |
| 5 | RAL+FTR+DRV/r+3TC/AZT | 17.9 | 5 | 8 | 2 |
| 5 | RAL+FTR+DRV/c+AZT+FTC | 17.95 | 5 | 8 | 2 |
| 5 | RAL+IBA+AZT+FTC | 18.1 | 4 | 5 | 2 |
| 5 | RAL+FTR+DRV/r+AZT+FTC | 18.1 | 5 | 9 | 2 |
| 5 | IBA+DRV/c+3TC/AZT | 18.3 | 4 | 3 | 2 |
| 5 | RAL+IBA+DRV/c+3TC/AZT | 18.35 | 5 | 5 | 2 |
| 5 | IBA+DRV/r+3TC/AZT | 18.5 | 4 | 4 | 2 |
| 5 | IBA+DRV/c+AZT+FTC | 18.5 | 4 | 4 | 2 |
| 5 | LEN+DRV/r+3TC/AZT | 18.5 | 4 | 4 | 2 |
| 5 | LEN+DRV/c+3TC/AZT | 18.55 | 4 | 3 | 2 |
| 5 | RAL+IBA+DRV/c+AZT+FTC | 18.55 | 5 | 6 | 2 |
| 5 | LEN+RAL+IBA+ETR | 18.65 | 4 | 4 | 2 |
| 5 | RAL+IBA+DRV/r+3TC/AZT | 18.65 | 5 | 6 | 2 |
| 5 | IBA+DRV/r+AZT+FTC | 18.7 | 4 | 5 | 2 |
| 5 | LEN+DRV/r+AZT+FTC | 18.7 | 4 | 5 | 2 |
| 5 | LEN+DRV/c+AZT+FTC | 18.75 | 4 | 4 | 2 |
| 5 | LEN+IBA+DRV/r+ETR | 18.75 | 4 | 4 | 2 |
| 5 | LEN+RAL+DRV/c+3TC/AZT | 18.85 | 5 | 5 | 2 |
| 5 | RAL+IBA+DRV/r+AZT+FTC | 18.85 | 5 | 7 | 2 |
| 5 | LEN+RAL+DRV/r+3TC/AZT | 18.9 | 5 | 6 | 2 |
| 5 | LEN+RAL+DRV/c+AZT+FTC | 19.05 | 5 | 6 | 2 |
| 5 | LEN+RAL+DRV/r+AZT+FTC | 19.1 | 5 | 7 | 2 |
| 5 | LEN+RAL+DRV/r+ETR | 19.35 | 4 | 6 | 2 |
| 5 | LEN+RAL+FTR+ETR | 19.4 | 4 | 6 | 2 |
| 5 | LEN+FTR+DRV/r+ETR | 19.6 | 4 | 6 | 2 |
Report
Preferred regimen based on the HIV-ASSIST algorithm: DTG/3TC
DTG/3TC had the lowest weighted score (1) among all regimens HIV-ASSIST evaluated. In general, lower HIV-ASSIST weighted scores are considered preferable with respect to achieving viral suppression and maximizing tolerability. Your patient may have other considerations we did not factor and this report should not be considered a guarantee of likely success with this patient. Please use clinical judgement in making final ARV selections. Other regimens you may wish to consider are listed below. A full list of ARV regimens analyzed by the HIV-ASSIST algorithm can be found by clicking the Expert Tab above.
| Score Code | Regimen | Weighted Score | Active Drugs | Total Pills | Frequency (x/day) |
|---|---|---|---|---|---|
| 1 | DTG/3TC | 1 | 2 | 1 | 1 |
The rationale behind why this regimen was chosen by our algorithm as the most appropriate is shown below:
Other highly ranked regimens
Other highly ranked regimens based on the HIV-ASSIST algorithm are shown below. For full details on these regimens, please click on the Expert Tab above.
| Score Code | Regimen | Weighted Score | Active Drugs | Total Pills | Frequency (x/day) |
|---|---|---|---|---|---|
| 1 | DTG/RPV | 1.01 | 2 | 1 | 1 |
| 1 | 3TC+DTG/RPV | 1.26 | 3 | 2 | 1 |
| 1 | DOR+DTG/3TC | 1.26 | 3 | 2 | 1 |
| 1 | BIC/TAF/FTC | 1.5 | 3 | 1 | 1 |
Mutations
Based on the Stanford Database, we assign penalties to various regimens based on inputted (i.e., genotypic) and assumed archived mutations. We consider drugs with summed mutation scores between 10 and 29 to have low-level resistance, scores between 30 and 59 to have intermediate-level resistance, and scores above 60 to have high-level resistance.
* signifies an assumed archived mutation based on prior treatment experience.| NRTI Mutation(s) | 3TC | FTC | ABC | TAF | TDF | AZT | D4T | DDI |
|---|---|---|---|---|---|---|---|---|
| Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NNRTI Mutation(s) | EFV | ETR | RPV | NVP | DOR |
|---|---|---|---|---|---|
| Total | 0 | 0 | 0 | 0 | 0 |
| PI Mutation(s) | LPVr | FPVr | TPVr | SQVr | IDVr | NFV | ATVr | ATVc | ATV | DRV | DRVr | DRVc |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| INSTI Mutation(s) | RAL | EVGc | DTG | BIC | CAB |
|---|---|---|---|---|---|
| Total | 0 | 0 | 0 | 0 | 0 |
| EI Mutation(s) | MVC | IBA | FOS |
|---|---|---|---|
| Total | 0 | 0 | 0 |
| CI Mutation(s) | LEN |
|---|---|
| Total | 0 |
Comorbidities, Side Effects, and Pregnancy Interactions
HIV-ASSIST incorporates a mathematical penalty into our algorithms for ARVs that are less preferred due to comorbidities or side-effects, based on recommendations from DHHS guidelines and HIV-ASSIST clinician and pharmacist expertise. In general, higher penalties suggest that the listed ARV is less favored in the presence of the stated comorbidity or side effect.
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 1
- HIV-ASSIST Notes:
- ABC is associated with an increased risk of MI in some cohort studies. Risk greatest in patients with traditional CVD. Consider avoiding ABC-based regimens.
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 1
- HIV-ASSIST Notes:
- ddI is associated with an increased risk of MI in some cohort studies. Risk greatest in patients with traditional ASCVD.
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 1
- HIV-ASSIST Notes:
- LPV can cause PR Prolongation. Risks include pre-existing heart disease and other medications.
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 1
- HIV-ASSIST Notes:
- SQV can cause PR Prolongation. Risks include pre-existing heart disease and other medications.
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0.5
- HIV-ASSIST Notes:
- ATV can cause PR Prolongation. Risks include pre-existing heart disease and other medications.
- Penalty:
- 0.5
- HIV-ASSIST Notes:
- ATV can cause PR Prolongation. Risks include pre-existing heart disease and other medications.
- Penalty:
- 0.5
- HIV-ASSIST Notes:
- ATV can cause PR Prolongation. Risks include pre-existing heart disease and other medications.
- Penalty:
- 0.1
- HIV-ASSIST Notes:
- DRV could potentially be associated with increased CV risk based on a recent 2017 study that finds "cumulative use of darunavir boosted by ritonavir was independently associated with a small but gradually increasing CVD risk."
- Penalty:
- 0.1
- HIV-ASSIST Notes:
- DRV could potentially be associated with increased CV risk based on a recent 2017 study that finds "cumulative use of darunavir boosted by ritonavir was independently associated with a small but gradually increasing CVD risk."
- Penalty:
- 0.1
- HIV-ASSIST Notes:
- DRV could potentially be associated with increased CV risk based on a recent 2017 study that finds "cumulative use of darunavir boosted by ritonavir was independently associated with a small but gradually increasing CVD risk."
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0.5
- HIV-ASSIST Notes:
- TAF is associated with small declines in bone mineral density.
- Penalty:
- 1
- HIV-ASSIST Notes:
- TDF is associated with greater decrease in bone mineral density and and osteomalacia. Consider avoiding TDF. If HLA-B*5701 negative and low viral load can use ABC/3TC.
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
- Penalty:
- 0
Co-medication Interactions
We have identified the following possible drug interactions which HIV-ASSIST factors into ARV regimen selection, based on recommendations from DHHS guidelines, University of Liverpool HIV Drug Interaction Checker, and HIV-ASSIST clinician and pharmacist expertise. Penalties less than 1.0 are typically those representing minor interactions that can be mediated by dosage adjustments, whereas a penalty of 2.0 represents medically contraindicated ARVs.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration. Dose Descovy according to the concomitant antiretroviral.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Co-administration has not been studied but no effect on lisinopril is expected. No dose adjustment is required. Pifeltro Summary of Product Characteristics, Merck Sharp & Dohme Ltd, November 2018., Summary:Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on the metabolism/elimination and toxicity profiles of both drugs, there is little potential for interaction as lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumab’s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Lisinopril is eliminated unchanged renally whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Lisinopril is eliminated unchanged renally via glomerular filtration.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Emtricitabine and tenofovir alafenamide do not interact with this metabolic pathway. Dose Descovy according to the concomitant antiretroviral.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6 but rilpivirine at a dose of 25 mg once daily is unlikely to have a clinically relevant effect on the exposure of medicinal products metabolised by CYP enzymes.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Doravirine does not inhibit or induce CYP enzymes.
- Penalty:
- 1
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol). Use caution when using Sotalol as there is potential for QTc prolongation.
- Liverpool Interaction Status:
- Amber/Moderate: Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- The impact on the PR interval of coadministration of Kaletra with other drugs that prolong the PR interval (including beta-adrenergic blockers) has not been evaluated. As a result, coadministration of Kaletra with these drugs should be undertaken with caution, particularly with those drugs metabolized by CYP3A. Clinical monitoring is recommended. Kaletra Prescribing Information, AbbVie Inc, October 2020. A case report describes a patient stable on lacidipine, ramipril, levothyroxine, rosuvastatin, metoprolol and acetylsalicylic acid who developed extreme bradycardia (20-25 bpm) and hypotension (50/20 mmHg) 48 hours after starting HIV post-exposure prophylaxis (tenofovir, emtricitabine, lopinavir/ritonavir). Lopinavir/ritonavir, lacidipine, ramipril and metoprolol were discontinued. Raltegravir was prescribed on day 4. Lacidipine, ramipril were re-instated on day 7 and metoprolol on day 9. Blood concentrations were analyzed approximately 12 h after the last dose of tenofovir/emtricitabine and 20 h after the last dose of lopinavir/ritonavir. Lopinavir, ritonavir, tenofovir and emtricitabine plasma concentrations were 8.40 mg/L, 0.29 mg/L, 0.059 mg/L and 0.12 mg/L, respectively. The lopinavir plasma concentration was higher than usual (3 to 7 mg/L); but the measurement was done only 3 days after treatment initiation while 2 weeks are required to see the maximal enzyme inducing effects of ritonavir. Tenofovir and emtricitabine plasma concentrations were in the normal range. Genetic analysis showed the patient to be an intermediate metaboliser for CYP2D6, a normal metaboliser for CYP3A4 and a low expressor of P-gp. The authors propose that the AV block and the hypotension were primarily associated with co-administration of the lopinavir/ritonavir combination with metoprolol and lacidipine as the patient was asymptomatic while he started antiretroviral therapy, and discontinuation of lopinavir/ritonavir, lacidipine, ramipril and metoprolol, restored normal rhythm, and further, re-introduction of lacidipine, ramipril and metoprolol without lopinavir/ritonavir induced no bradyarrythmia. Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir. Puech R, Gagnieu M-C, Planus C, et al. Br J Clin Pharmacol, 2011, 71(4): 621-623., Summary:Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Coadministration could potentially increase metoprolol concentrations, although to a moderate extent. Pharmacokinetic studies between lopinavir/ritonavir and drugs that prolong the PR interval including beta blockers have not been performed. An additive effect of lopinavir and these drugs cannot be excluded. A case report described a patient stable on lacidipine, ramipril, levothyroxine, rosuvastatin, metoprolol and acetylsalicylic acid who developed extreme bradycardia (20-25 bpm) and hypotension (50/20 mmHg) 48 hours after starting HIV post-exposure prophylaxis (tenofovir, emtricitabine, lopinavir/ritonavir). The authors propose that the AV block and the hypotension were primarily associated with co-administration of the lopinavir/ritonavir combination with metoprolol and lacidipine as the patient was asymptomatic while he started antiretroviral therapy. Discontinuation of lopinavir/ritonavir, lacidipine, ramipril and metoprolol, restored normal rhythm, and further, re-introduction of lacidipine, ramipril and metoprolol without lopinavir/ritonavir induced no bradyarrythmia. Note, PR interval monitoring may be warranted in patients with underlying block or those with atrioventricular nodal blocking agents.
- Penalty:
- 0.75
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol)
- Liverpool Interaction Status:
- Yellow/Moderate-low: Potential Weak Interaction (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Fosamprenavir/ritonavir could potentially increase metoprolol concentrations, although to a moderate extent. No a priori dosage adjustment is required.
- Penalty:
- 0.75
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol)
- Liverpool Interaction Status:
- RED/High: Do Not Coadminister (Moderate Quality of Evidence)
- Liverpool Notes:
- Co-administration of tipranavir with low dose ritonavir, with drugs that are highly dependent on CYP2D6 for clearance, such as the antiarrhythmic metoprolol (given in heart failure), is contraindicated. Based on theoretical considerations, tipranavir, co-administered with low dose ritonavir, is expected to increase metoprolol concentrations.Aptivus Summary of Product Characteristics, Boehringer Ingelheim Ltd, July 2020., Summary:Coadministration of tipranavir/ritonavir and drugs that are highly dependent on CYP2D6 for clearance, such metoprolol (given in heart failure), is contraindicated. Coadministration may increase metoprolol concentrations.
- Penalty:
- 0.75
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol). Use caution when using Sotalol as there is potential for QTc prolongation.
- Penalty:
- 0.75
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol)
- Liverpool Interaction Status:
- Yellow/Moderate-low: Potential Weak Interaction (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Indinavir/ritonavir could potentially increase metoprolol concentrations, although to a moderate extent. No a priori dosage adjustment is required. An interaction is unlikely with unboosted indinavir.
- Penalty:
- 0.75
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol)
- Penalty:
- 1
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol). Use caution when using Sotalol as there is potential for QTc prolongation.
- Liverpool Interaction Status:
- Amber/Moderate: Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Atazanavir/ritonavir could potentially increase metoprolol concentrations, although to a moderate extent. Pharmacokinetic studies between atazanavir and drugs that prolong the PR interval including beta blockers (other than atenolol) have not been performed. An additive effect of atazanavir and these drugs cannot be excluded. Note, PR interval monitoring may be warranted in patients with underlying block or those with atrioventricular nodal blocking agents.
- Penalty:
- 1
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol). Use caution when using Sotalol as there is potential for QTc prolongation.
- Liverpool Interaction Status:
- Amber/Moderate: Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Concentrations of beta-blockers may be increased when coadministered with Evotaz. The mechanism of interaction is inhibition of CYP2D6 by cobicistat. Clinical monitoring is recommended when coadministered with Evotaz and a dose reduction of the beta-blocker may be necessary. Evotaz Summary of Product Characteristics, Bristol-Myers Squibb Pharmaceuticals Ltd, November 2018. Coadministration may increase beta-blocker concentrations but have no effect on atazanavir concentrations. Clinical monitoring is recommended when beta-blockers that are metabolized by CYP2D6 are coadministered with Evotaz. Evotaz US Prescribing Information Bristol-Myers Squibb Company, March 2018., Summary:Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Atazanavir/cobicistat could potentially increase metoprolol concentrations although to a moderate extent as cobicistat is a weak inhibitor of CYP2D6. Pharmacokinetic studies between atazanavir and drugs that prolong the PR interval including beta blockers (other than atenolol) have not been performed. An additive effect of atazanavir and these drugs cannot be excluded. Note, PR interval monitoring may be warranted in patients with underlying block or those receiving known atrioventricular nodal blocking agents. The atazanavir/cobicistat SmPC recommends clinical monitoring. A dose reduction of metoprolol may be necessary.
- Penalty:
- 0.25
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol). Use caution when using Sotalol as there is potential for QTc prolongation.
- Liverpool Interaction Status:
- Amber/Moderate: Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a pharmacokinetic interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Atazanavir alone does not inhibit CYP2D6. Pharmacokinetic studies between atazanavir and drugs that prolong the PR interval including beta blockers (other than atenolol) have not been performed. An additive effect of atazanavir and these drugs cannot be excluded. Note, PR interval monitoring may be warranted in patients with underlying block or those receiving known atrioventricular nodal blocking agents.
- Penalty:
- 1
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol)
- Liverpool Interaction Status:
- Yellow/Moderate-low: Potential Weak Interaction (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. Co-administration of darunavir and ritonavir with medicinal products which are primarily metabolised by CYP2D6 (such as metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions. Clinical monitoring is recommended when co-administering boosted darunavir with beta-blockers. A lower dose of the beta-blocker should be considered. Prezista Summary of Product Characteristics, Janssen-Cilag Ltd, September 2022. Coadministration with darunavir/ritonavir may increase metoprolol concentrations. Clinical monitoring of patients is recommended. A dose decrease may be needed for this drug when co-administered with darunavir/ritonavir and a lower dose of the beta blocker should be considered. Prezista Prescribing Information, Janssen Pharmaceuticals Inc, March 2023., Summary:Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Darunavir/ritonavir could potentially increase metoprolol concentrations, although to a limited extent. No a priori dosage adjustment is required.
- Penalty:
- 1
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol)
- Liverpool Interaction Status:
- Yellow/Moderate-low: Potential Weak Interaction (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. Co-administration of darunavir and ritonavir with medicinal products which are primarily metabolised by CYP2D6 (such as metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions. Clinical monitoring is recommended when co-administering boosted darunavir with beta-blockers. A lower dose of the beta-blocker should be considered. Prezista Summary of Product Characteristics, Janssen-Cilag Ltd, September 2022. Coadministration with darunavir/ritonavir may increase metoprolol concentrations. Clinical monitoring of patients is recommended. A dose decrease may be needed for this drug when co-administered with darunavir/ritonavir and a lower dose of the beta blocker should be considered. Prezista Prescribing Information, Janssen Pharmaceuticals Inc, March 2023., Summary:Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Darunavir/ritonavir could potentially increase metoprolol concentrations, although to a limited extent. No a priori dosage adjustment is required.
- Penalty:
- 1
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol)
- Liverpool Interaction Status:
- Yellow/Moderate-low: Potential Weak Interaction (Very Low Quality of Evidence)
- Liverpool Notes:
- Based on theoretical considerations darunavir/cobicistat is expected to increase metoprolol plasma concentrations (CYP3A inhibition). Clinical monitoring is recommended when co-administering darunavir/cobicistat with beta-blockers and a lower dose of the beta-blocker should be considered. Rezolsta Summary of Product Characteristics, Janssen-Cilag Ltd, July 2023. Coadministration is expected to increase concentrations of metoprolol. Clinical monitoring is recommended for co-administration with beta-blockers that are metabolized by CYP2D6. Prezcobix US Prescribing Information, Janssen Pharmaceuticals Inc, March 2023., Summary:Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Darunavir/cobicistat could potentially increase metoprolol concentrations although to a limited extent as cobicistat is a weak inhibitor of CYP2D6. No a priori dosage adjustment is needed.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6.
- Penalty:
- 1
- HIV-ASSIST Notes:
- Possible increase in level of beta blocker (particularly with metoprolol, timolol, carvedilol, propranolol). May need to decrease beta blocker dose. Adjust dose based on clinical response. Consider using beta blockers that are not metabolized by CYP450 enzymes (ex. Atenolol, labetalol, nadolol, sotalol)
- Liverpool Interaction Status:
- Yellow/Moderate-low: Potential Weak Interaction (Very Low Quality of Evidence)
- Liverpool Notes:
- Interaction not studied with any of the components of Genvoya. Concentrations of beta-blockers may be increased when co-administered with cobicistat. Clinical monitoring is recommended and a dose decrease may be necessary when these agents are co-administered with Genvoya. Genvoya Summary of Product Characteristics, Gilead Sciences International Ltd, November 2021. Coadministration is expected to increase concentrations of beta-blockers. Clinical monitoring is recommended and a dosage decrease of the beta blocker may be necessary when these agents are coadministered with Genvoya. Genvoya Prescribing Information, Gilead Sciences Inc, September 2021., Summary:Coadministration has not been studied. Metoprolol is mainly metabolized by CYP2D6. Elvitegravir/cobicistat could potentially increase metoprolol concentrations although to a moderate extent as cobicistat is a weak inhibitor of CYP2D6. Emtricitabine and tenofovir alafenamide do not interact with this metabolic pathway. No a priori dosage adjustment is required.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6, however, dolutegravir is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Bictegravir does not inhibit or induce P450 enzymes; emtricitabine and tenofovir alafenamide do not interact with metoprolol’s metabolic pathway.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Cabotegravir does not inhibit or induce CYP enzymes at clinically relevant concentrations.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6, however, maraviroc is not expected to inhibit or induce CYP450 enzymes at clinically relevant concentrations.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumab’s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Metoprolol undergoes hepatic metabolism whereas ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Fostemsavir is a prodrug and is hydrolysed to the active compound temsavir in the small intestine. Temsavir is mainly metabolized by esterase-mediated hydrolysis with a small contribution of CYP3A4. Temsavir does not inhibit or induce CYP enzymes. In addition, fostemsavir did not have a clinically meaningful effect on PR interval.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metoprolol is mainly metabolized by CYP2D6. Lenacapavir is mainly cleared as unchanged drug and has no inhibitory or inducing effects on CYP2D6.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product. Dose Descovy according to the concomitant antiretroviral.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely with intramuscular cabotegravir. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. However, this interaction is not relevant when cabotegravir is administered intramuscularly.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. No drug interaction studies have been conducted with ibalizumab: based on ibalizumab’s mechanism of action and target-mediated drug disposition, drug-drug interactions are not expected. Ibalizumab, a monoclonal antibody binding to the CD4 receptor, is likely to be eliminated via intracellular catabolism similarly to other monoclonal antibodies.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.
- Penalty:
- 0
- Liverpool Interaction Status:
- Green/Low: No Interaction Expected (Very Low Quality of Evidence)
- Liverpool Notes:
- Coadministration has not been studied. If taken at the same time, it is likely that food and beverages (including mineral water), calcium supplements, antacids, and some oral medicinal products will interfere with absorption of alendronate. Therefore, patients must wait at least 30 minutes after taking alendronate before taking any other oral medicinal product.